RE:RE:RE:Ph 1b patients #5 and #6 still cancer free after 2 yearsLangosta ... It's all about market shares. Whether you're TESLA, AMAZON, MERCK, GOOGLE, FACEBOOK, etc ...
You're the CEO of a big pharma and have stock options. Why would you let an opportunity run away? Why would you let a competitor shift you?
TLT had its Ph. 2 to do. It won't even be completed until 2025. What was the rush for those big pharmas, when they had, in the meantime, other drugs to bring to markets.
Now, with Ph. 2 data, it's a different story though. Commercial revenues are projected for Jan. 2023. Accelerated Approval program???
Differences of cultures also sometimes make a transaction look bad.
The agreement ends several months of back-and-forth between the two drugmakers, which included J&J at one point walking away. That's when Actelion struck up talks with Sanofi. But the way Actelion chairman Jean-Pierre Garnier sees it, the relatively complex deal arrangement was worth the wait.
“When a Big Pharma buys a smaller company, very often there’s also destruction of value. ... They don’t have the same culture, they don’t have the same processes," Garnier said on a Thursday conference call. "There’s always this dark side to the transaction. Today, we have found the structure that pretty much avoids these dark sides.”
“I do believe today that R&D NewCo will be a very successful company,” Clozel—who will run the new spinoff—added on the call.